We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

CRISPR Test Diagnoses Mpox Faster Than Lab-Based PCR Method

By LabMedica International staff writers
Posted on 14 Feb 2024

Image: CRISPR is combined with nanopore sensing technology to detect whether or not mpox is present in a sample (Photo courtesy of 123RF)

Image: CRISPR is combined with nanopore sensing technology to detect whether or not mpox is present in a sample (Photo courtesy of 123RF)

Mpox, formerly known as monkeypox, is a rare viral disease transmitted through physical contact and typically presents mild symptoms like fever, rash, and swollen lymph nodes, though severe cases can require medical intervention. Due to its contagious nature, prompt testing is crucial for isolation and treatment purposes. Current mpox testing requires laboratory equipment and may take hours to yield results. Now, new research suggests a way for faster mpox testing that could be done in any clinic.

Researchers at Pennsylvania State University (University Park, PA, USA) have utilized CRISPR, the groundbreaking gene-editing technology, to develop a faster mpox test. For their study, the team designed a genetic sequence with an attached reporter specifically targeting the mpox virus. The test employs programmable CRISPR RNA that binds to the target and a protein called Cas12a, which together cleaves the reporter to produce fragments of varying sizes. Using nanopore sensing technology, these reporter fragments are analyzed to rapidly and accurately determine the presence of mpox in a sample.

The specificity of the test was validated by its inability to detect cowpox virus, a relative of mpox, thereby confirming its exclusive sensitivity to mpox. This testing method significantly reduces the detection time, taking only 32 to 55 minutes depending on the viral load, compared to the longer duration required for PCR lab testing. The research team is exploring the application of this nanopore technology for the development of tests for other pathogens, aiming to enable multi-target testing from a single sample using a portable device. Although this technology is not yet commercially available, the researchers hope to create a device that could facilitate widespread pathogen testing.

Related Links:
Pennsylvania State University

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®

New

Alzheimer's Disease Biomarker Assay

Elecsys Phospho-Tau (217P) Plasma

New

Gold Member

Fully-auto Specific Protein (Nephelometry) Analyzer

PA240

Latest Microbiology News

Channels

Clinical Chemistry

view channel

Image: The recommendations advise PSA testing every two years for average-risk men aged 50–69, with screening beginning at 45 for Black men and those with a strong family history.( Image Credit: iStock)

Updated PSA Testing Guidelines Support Early Prostate Cancer Detection

Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more

Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker

Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read more

Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease

Huntington’s disease is a genetic disorder caused by a mutation in the HTT gene that progressively affects movement, cognition, behavior, and independence. Although mutation carriers can be identified... Read more

New Biomarker Offers Longer Detection Window for Suspected GHB Exposure

Gamma-hydroxybutyrate (GHB) can be used recreationally or administered covertly to incapacitate victims. Forensic confirmation is challenging because the substance is rapidly eliminated, with typical detection... Read more

Molecular Diagnostics

view channel

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases

Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more

Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma

Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read more

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Hematology

view channel

Image: New research using stored blood samples collected over time has traced the development of AML years to decades before diagnosis (Image Credit: Shutterstock)

Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis

Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more

Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic

Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read more

Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Image: Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3 (Photo courtesy of Roche)

Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel

Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more

Pathology

view channel

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment

Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more

Technology

view channel

New qPCR Master Mixes Offer Broad Compatibility for Routine Research

Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more

Image: Key modules and interactions in the LabARIA agentic system. (Yang, H.S., Pan, W., Cushing, M.M. et al. An agentic framework for intelligent clinical laboratory medicine. npj Health Systems (2026). https://doi.org/10.1038/s44401-026-00163-3)

Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring

Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read more

Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing

PCR amplifies DNA to enable highly accurate testing, but its reliance on complex, expensive laboratory analyzers has traditionally kept many workflows in centralized settings. A new personal DNA analyzer... Read more

Image: Device schematic and experimental workflow (Williams, E.K., Zhang, D.Y., Alese, T.T. et al. Nature Biomedical Engineering, 2026. https://doi.org/10.1038/s41551-026-01818-0)

Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia

Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more

Industry

view channel

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more

Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia

Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more